Allison Gordon
Memorial Sloan Kettering Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Allison Gordon as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:48 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07895498 · A Study of Standard of Care Drugs With or Without Ivermectin for Daraxonrasib-Induced Skin Toxicity in People With Pancreatic CancerMemorial Sloan Kettering Cancer Center · recruiting · Pancreatic Cancer, Skin Toxicities · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:48 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:48 UTC. The ranking covers the 200 most relevant of 248 PubMed records, and a shared surname and initials can bring in a namesake. All 248 on PubMed
- Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.N Engl J Med · 20211,527 citationsRCR 89.2
- Vasopressin versus norepinephrine infusion in patients with septic shock.N Engl J Med · 20081,309 citationsRCR 38.4
- Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan.J Clin Oncol · 2001961 citationsRCR 21.0
- Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.N Engl J Med · 2021788 citationsRCR 47.4
- Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.N Engl J Med · 2021753 citationsRCR 43.8
- 678 citationsRCR 30.5
- 546 citationsRCR 23.1
- Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.J Clin Oncol · 1997542 citationsRCR 14.1
- Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma.Gastroenterology · 2016537 citationsRCR 21.8
- Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.J Natl Cancer Inst · 2004471 citationsRCR 10.5